A guy whose last gig involved the development of artificial kidneys will now turn his attention to creating cell and gene therapies designed in part to help restore eyesight and treat Alzheimer’s.

Kaigham J. Gabriel, a former Carnegie Mellon University professor, has been appointed as chief executive officer of BioForge, the $250 million University of Pittsburgh biomanufacturing facility planned at Hazelwood Green in Hazelwood.

In his new job, Mr. Gabriel will help shepherd the complex to life and oversee its operation, with the mission of devising cell and gene therapies that could be used to treat cancers and other disorders like Alzheimer’s and Parkinson’s disease and help restore eyesight.

Before joining Pitt, Mr. Gabriel worked as the founding chief operating officer at Los Angeles-based Wellcome Leap, a nonprofit created to speed up the development of medical and health care treatments.

Advertise with us

Under his leadership, in just over two years, Wellcome developed 10 multimillion-dollar programs, including those focused on artificial kidneys, the biology of depression, next-generation surgical delivery, and resilient aging, Pitt stated in announcing Mr. Gabriel’s appointment.

“Ken’s depth of experience as an innovator across government, academic and commercial sectors makes him a perfect fit for leveraging Pitt’s world-class research in medicine and the health sciences at BioForge,” Anantha Shekhar, Pitt’s senior vice chancellor for the health sciences, said in a statement.

“His leadership will facilitate breakthroughs and accelerate commercial development that will benefit countless patients while also partnering with the Hazelwood community to introduce new opportunities for growth in an inclusive and sustainable way.”

Mr. Gabriel’s appointment comes as Pitt prepares to start construction on BioForge later this winter at the site of the former LTV coke plant in Hazelwood. The university authorized the purchase of the 3-acre property for $10 million about a year ago.

“The best treatment for you is you. That’s the power and promise of biologic precision medicines — they are medicines designed to recruit your own body’s capabilities to heal,” Mr. Gabriel said a statement.

Advertise with us

“BioForge’s mission is to accelerate breakthroughs in both the development and manufacturing of precision medicines to speed their delivery, use and impact.”

Before joining Wellcome Leap, Mr. Gabriel served as president and CEO of Draper, an MIT spinoff that developed the Apollo guidance computer in the 1960s.

There he helped to broaden Draper’s reach to include biomedical innovations in end-to-end cell therapy, engineered human organ-on-a-chip platforms for drug discovery and the world’s first adaptive pediatric heart valve, Pitt stated.

In addition, Mr. Gabriel, who also will be director of Pitt’s Advanced Biomanufacturing Institute, is a former professor in the electrical & computer engineering department and the Robotics Institute at CMU.

As part of BioForge, Pitt has already reached a deal with ElevateBio, a Cambridge, Mass.-based company that specializes in the development of cell and gene therapies, to become the first tenant.

Advertise with us

Under the 30-year agreement, ElevateBio will build BaseCamp, an 80,000-square-foot facility that will focus on the research, development and manufacturing of cell and gene therapeutics and technologies.

Overall, the BioForge complex is expected to total about 230,000 square feet. It is funded with the help of a $100 million grant from the Richard King Mellon Foundation. The grant is the largest for a single project in the foundation’s history.

Mark Belko: mbelko@post-gazette.com